Clinical Trials for Liver Cancer

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: First-line trial in adults with unresectable/advanced HCC (BCLC B not LRT-eligible or C; Child-Pugh A; ECOG 0–1; no prior systemic therapy) comparing rilvegostomig (PD-1/TIGIT bispecific) plus bevacizumab with or without tremelimumab (CTLA-4) versus standard atezolizumab (PD-L1) plus bevacizumab. Excludes significant bleeding risk/anticoagulation needs, active autoimmune disease requiring immunosuppression, CNS mets, hepatic encephalopathy, and prior anti-CTLA-4/TIGIT.

ClinicalTrials.gov ID: NCT06921785

Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, systemic therapy–naïve HCC (ECOG 0–1, Child-Pugh A) receive triplet therapy with zanzalintinib (XL-092; oral multikinase TKI targeting VEGFR2/MET/TAM), durvalumab (PD-L1 inhibitor) every 4 weeks, and a single priming dose of tremelimumab (CTLA-4 inhibitor), with cohorts exploring sequencing (TKI lead-in vs immediate I/O). Excludes prior PD-1/PD-L1/CTLA-4 or MET/VEGFR TKIs, significant autoimmune disease, active viral hepatitis/HIV, and high bleeding risk; mandatory baseline tumor tissue required.

ClinicalTrials.gov ID: NCT06698250

Phase II Basket Trial of Ligufalimab (AK117) and Cadonilimab (AK104) in Advanced Hepatobiliary Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic hepatocellular carcinoma (Child-Pugh A/B7; non-fibrolamellar) or biliary tract cancers, all progressed on prior anti–PD-1/PD-L1 therapy and ECOG 0–1, receive intravenous ligufalimab (anti‑CD47 macrophage‑activating mAb) plus cadonilimab (bispecific anti‑PD‑1/CTLA‑4 checkpoint inhibitor) every 21 days until progression/toxicity. Excludes prior liver transplant, active autoimmune disease requiring systemic therapy, uncontrolled infection, and active CNS disease; HBV/HCV-associated HCC allowed with antiviral management.

ClinicalTrials.gov ID: NCT06789848

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with recurrent or metastatic solid tumors—including endometrial, head and neck, pancreatic, colorectal, hepatocellular, gastric, urothelial, ovarian, cervical, biliary tract, certain subtypes of breast cancer, and cutaneous melanoma—whose disease has progressed after standard therapy and who have measurable, biopsiable disease. All patients receive ifinatamab deruxtecan, an investigational B7-H3-directed antibody-drug conjugate delivering a topoisomerase I inhibitor, administered intravenously every three weeks.

ClinicalTrials.gov ID: NCT06330064

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic, pMMR/MSS colorectal adenocarcinoma (no liver or CNS metastases, ECOG 0-1, no prior systemic therapy for metastatic disease) to evaluate the addition of volrustomig—a bispecific anti-PD-1/CTLA-4 antibody—to FOLFIRI and bevacizumab versus standard FOLFIRI plus bevacizumab. Volrustomig is designed to enhance immune response by targeting CTLA-4 selectively on PD-1+ T cells.

ClinicalTrials.gov ID: NCT06792695

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Untreated adults with unresectable/locally advanced or metastatic HCC (BCLC B–C; Child-Pugh A–B7; ECOG 0–1) are randomized to livmoniplimab (anti-GARP/TGF-β1) plus budigalimab (anti–PD-1) versus first-line immunotherapy standards (atezolizumab–bevacizumab or tremelimumab plus durvalumab). The study optimizes dosing in Stage 1 and then compares the selected combo against tremelimumab/durvalumab, treating until progression.

ClinicalTrials.gov ID: NCT06109272

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic or unresectable HCC or ICC with at least one measurable and injectable lesion; HCC cohort requires progression after ≥2 prior systemic lines (including prior IO/anti‑angiogenic), ICC cohort after first‑line chemo (with required prior IDH1 inhibitor if IDH1‑mutant and PD‑1 inhibitor if MSI‑H). Investigational therapy is intratumoral VG161, an engineered oncolytic HSV‑1 expressing IL‑12, IL‑15/IL‑15Rα, and a PD‑1/PD‑L1–blocking peptide, given as monotherapy or combined with nivolumab.

ClinicalTrials.gov ID: NCT05223816

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic HCC (Child-Pugh A, ECOG 0–1) who progressed after exactly one prior PD‑1/PD‑L1–based regimen and have measurable, injectable disease receive intratumoral RP2 plus atezolizumab and bevacizumab. RP2 is an oncolytic HSV‑1 engineered to express GALV‑GP‑R−, GM‑CSF, and a locally acting anti–CTLA‑4 molecule to drive oncolysis and antitumor immunity; key exclusions include high-risk varices, Vp4/macrovascular invasion, active herpetic infection, uncontrolled HBV, and significant autoimmune or bleeding risks.

ClinicalTrials.gov ID: NCT05733598

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced, non-curable HCC and Child-Pugh B7 cirrhosis after 1–2 prior systemic therapies (ECOG 0–1) are randomized 2:1 to oral namodenoson 25 mg BID versus placebo. Namodenoson is a selective adenosine A3 receptor agonist targeting tumor/inflamed liver A3AR with downstream PI3K/AKT, NF-κB, and Wnt/β-catenin modulation; prior phase II suggested a survival signal in CP-B7 with favorable tolerability.

ClinicalTrials.gov ID: NCT05201404